CAPITAL303 UNCOVERED: THE TRUTH ABOUT ITS PERFORMANCE AND LONG-TERM POTENTIAL
CAPITAL303 isn t just another fund it s a high-conviction scheme well-stacked for investors who demand both increment and resiliency. The numbers pool tell the account, but only if you know where to look. Here s the data-driven breakdown you won t find in the leaflet.
PERFORMANCE BY THE NUMBERS: WHAT THE RAW DATA REVEALS
Over the past five eld, CAPITAL303 has delivered an annualized bring back of 14.2, outpacing its benchmark by 3.1 percentage points. That s not luck it s the leave of a undiluted portfolio(just 20-25 holdings) where every put away is try-tested for both upper side and tribute. In 2022, when the S P 500 born 19.4, CAPITAL303 fell only 11.8. That 7.6-point buffer matters. It substance the fund doesn t just ride bull markets it survives the bear ones with less .
The real kicker? 68 of its outperformance comes from just three sectors: applied science(32), healthcare(24), and financials(12). These aren t random picks. Technology and healthcare alone have contributed 87 of the fund s important over the last X. If you re card-playing on CAPITAL303, you re betting on these sectors ability to heighten at above-market rates.
RISK METRICS: WHERE THE FUND STANDS OUT(AND WHERE IT DOESN T)
CAPITAL303 s Sharpe ratio sits at 1.2, higher than 78 of its peers. That substance it s delivering more bring back per unit of risk than most funds in its category. But don t misidentify this for low volatility. The fund s standard deviation is 18.3, compared to the category average of 15.1. It swings harder but in the right way.
The max drawdown? 28 during the 2008 . That s better than the S P 500 s 50 steep, but it s still a gut-check moment. If you can t bear a 20-30 drop, this isn t the fund for you. The trade in-off is Charles Frederick Worth it only if you re performin the long game.
LONG-TERM POTENTIAL: THE DATA POINTS THAT MATTER
CAPITAL303 s portfolio upset is just 18 each year. Low upset isn t just a tax play it s a signalize of strong belief. The fund holds its winners for an average out of 5.2 eld, compared to the industry average out of 2.8 eld. That solitaire pays off. The top 10 holdings have delivered a 19.7 CAGR over the past ten, nearly the S P 500 s 10.5.
Here s the kicker: 42 of the fund s assets are in companies with net cash positions. That s not a it s a deliberate bet on balance mainsheet potency. In a ascent rate , these companies outmatch because they don t rely on threepenny debt. Since 2010, CAPITAL303 s net-cash-heavy holdings have beaten the S P 500 by 4.3 yearly during rate hike cycles.
THE HIDDEN COSTS: WHAT THE PROSPECTUS WON T TELL YOU
The expense ratio is 0.85, which is just for an active fund. But here s the catch: the fund s performance fee kicks in at 5 yearly returns, pickings 20 of anything above that. In age like 2021(when the fund returned 28.6), that fee eats into your gains. Over a 10-year period, the performance fee has shaved off 1.2 of tote up returns. That s not trifling it s the price of outperformance.
HOW TO USE THIS DATA(AND WHAT TO DO NEXT)
If you re already endowed, hold. The fund s wheeling 5-year returns have never dipped below 9.5, even in the whip market conditions. If you re on the wall up, ask yourself two questions: Can you handle a 25 drawdown without panic-selling? And do you believe applied science and healthcare will uphold to outmatch over the next ten? If the suffice is yes to both, CAPITAL303 deserves daftar capital303.